Transaminase Test Market Size, Share & Trends Analysis Report By Test Type (ALT Test, AST Test, Combined Transaminase Panels), By Technology (Automated Analyzers, Semi-Automated & Manual Systems), By Application, By End Use, By Region, And Segment Forecas
Description
Transaminase Test Market Summary
The global transaminase test market size was estimated at USD 4.10 billion in 2024 and is projected to reach USD 7.81 billion by 2033, growing at a CAGR of 7.54% from 2025 to 2033. This market centers on rapid, accurate diagnostic platforms, such as AST (Aspartate Transaminase) and GOT (Glutamic Oxaloacetic Transaminase) assays, used extensively in liver function assessment, disease monitoring, and general health screening.
These platforms support timely clinical decisions, driven by increasing awareness of liver diseases and widespread integration into hospital, clinical, and point-of-care settings. The growth in the transaminase test industry is propelled by a combination of advancing technology and increasing access in emerging markets. Innovations in point-of-care AST/GOT devices-bolstered by AI-enabled interpretation-are reducing turnaround times and improving precision. Accessibility is expanding beyond well-resourced labs to outpatient clinics and rural settings, thanks to portable formats and software-driven automation.
Another major growth driver is the rising global burden of liver disease. The increasing prevalence of non-alcoholic fatty liver disease (NAFLD), viral hepatitis, and alcohol-related liver conditions underscores the need for regular transaminase screening. Coupled with aging populations and preventive health programs, demand is mounting for reliable, cost-effective liver biomarker tests.
In March 2025, the European Medicines Agency (EMA) approved the use of the artificial intelligence (AI) tool AIM-NASH in clinical trials to assess the severity of metabolic dysfunction-associated steatohepatitis (MASH), a severe form of fatty liver disease. Developed using machine learning, AIM-NASH was trained with over 100,000 annotations from 59 pathologists and evaluated more than 5,000 liver biopsies across nine large clinical trials. The EMA's human medicines committee confirmed that AIM-NASH can reliably determine disease activity from biopsies with less variability than the current standard, which typically relies on a consensus of three pathologists. This advancement is expected to enhance the clarity of evidence regarding the benefits of new treatments in clinical trials.
Overall, the global transaminase test market is experiencing significant transformation, driven by technological advancements and evolving healthcare needs. Integrating artificial intelligence (AI) into diagnostic platforms enhances the precision and efficiency of liver function assessments, enabling earlier detection and personalized treatment strategies. Point-of-care testing (POCT) expands access to liver diagnostics, particularly in remote and underserved regions, by providing rapid and convenient testing options. Furthermore, developing non-invasive diagnostic tools reduces reliance on traditional biopsy procedures, aligning with the growing preference for less invasive methods among patients and healthcare providers.
These innovations are improving patient outcomes and reshaping the competitive landscape, prompting key players to invest in research and development to stay at the forefront of the market. With the demand for efficient and accessible liver diagnostics continuing to rise, the market is well-positioned for sustained growth, offering opportunities for companies to leverage emerging technologies and meet the evolving needs of the global healthcare ecosystem.
Global Transaminase Test Market Report Segmentation
This report forecasts revenue growth and provides an analysis of the latest trends in each of the sub-segments from 2021 to 2033. For this report, Grand View Research has segmented the transaminase test market on the basis of test type, technology, application, end use, and region:
The global transaminase test market size was estimated at USD 4.10 billion in 2024 and is projected to reach USD 7.81 billion by 2033, growing at a CAGR of 7.54% from 2025 to 2033. This market centers on rapid, accurate diagnostic platforms, such as AST (Aspartate Transaminase) and GOT (Glutamic Oxaloacetic Transaminase) assays, used extensively in liver function assessment, disease monitoring, and general health screening.
These platforms support timely clinical decisions, driven by increasing awareness of liver diseases and widespread integration into hospital, clinical, and point-of-care settings. The growth in the transaminase test industry is propelled by a combination of advancing technology and increasing access in emerging markets. Innovations in point-of-care AST/GOT devices-bolstered by AI-enabled interpretation-are reducing turnaround times and improving precision. Accessibility is expanding beyond well-resourced labs to outpatient clinics and rural settings, thanks to portable formats and software-driven automation.
Another major growth driver is the rising global burden of liver disease. The increasing prevalence of non-alcoholic fatty liver disease (NAFLD), viral hepatitis, and alcohol-related liver conditions underscores the need for regular transaminase screening. Coupled with aging populations and preventive health programs, demand is mounting for reliable, cost-effective liver biomarker tests.
In March 2025, the European Medicines Agency (EMA) approved the use of the artificial intelligence (AI) tool AIM-NASH in clinical trials to assess the severity of metabolic dysfunction-associated steatohepatitis (MASH), a severe form of fatty liver disease. Developed using machine learning, AIM-NASH was trained with over 100,000 annotations from 59 pathologists and evaluated more than 5,000 liver biopsies across nine large clinical trials. The EMA's human medicines committee confirmed that AIM-NASH can reliably determine disease activity from biopsies with less variability than the current standard, which typically relies on a consensus of three pathologists. This advancement is expected to enhance the clarity of evidence regarding the benefits of new treatments in clinical trials.
Overall, the global transaminase test market is experiencing significant transformation, driven by technological advancements and evolving healthcare needs. Integrating artificial intelligence (AI) into diagnostic platforms enhances the precision and efficiency of liver function assessments, enabling earlier detection and personalized treatment strategies. Point-of-care testing (POCT) expands access to liver diagnostics, particularly in remote and underserved regions, by providing rapid and convenient testing options. Furthermore, developing non-invasive diagnostic tools reduces reliance on traditional biopsy procedures, aligning with the growing preference for less invasive methods among patients and healthcare providers.
These innovations are improving patient outcomes and reshaping the competitive landscape, prompting key players to invest in research and development to stay at the forefront of the market. With the demand for efficient and accessible liver diagnostics continuing to rise, the market is well-positioned for sustained growth, offering opportunities for companies to leverage emerging technologies and meet the evolving needs of the global healthcare ecosystem.
Global Transaminase Test Market Report Segmentation
This report forecasts revenue growth and provides an analysis of the latest trends in each of the sub-segments from 2021 to 2033. For this report, Grand View Research has segmented the transaminase test market on the basis of test type, technology, application, end use, and region:
- Test Type Outlook (Revenue, USD Million, 2021 - 2033)
- ALT Test
- AST Test
- Combined Transaminase Panels
- Others
- Technology Outlook (Revenue, USD Million, 2021 - 2033)
- Automated Analyzers
- Semi-Automated & Manual Systems
- Point-of-Care (POC) Devices
- Paper-Based / Lab-on-a-Chip Platforms
- Others
- Application Outlook (Revenue, USD Million, 2021 - 2033)
- Liver Disease Diagnosis & Monitoring
- Hepatitis Screening
- Drug-Induced Liver Injury (DILI) Monitoring
- Others
- End Use Outlook (Revenue, USD Million, 2021 - 2033)
- Hospitals & Clinics
- Diagnostic Laboratories (centralized testing)
- Research Institutes
- Home Testing
- Others
- Regional Outlook (Revenue, USD Million, 2021 - 2033)
- North America
- U.S.
- Canada
- Mexico
- Europe
- Germany
- UK
- France
- Italy
- Spain
- Denmark
- Sweden
- Norway
- Asia Pacific
- Japan
- China
- India
- Australia
- South Korea
- Thailand
- Latin America
- Brazil
- Argentina
- Middle East and Africa (MEA)
- South Africa
- Saudi Arabia
- UAE
- Kuwait
Table of Contents
150 Pages
- Chapter 1. Methodology and Scope
- 1.1. Market Segmentation
- 1.1.1. Market Definitions
- 1.2. Objectives
- 1.2.1. Objective - 1
- 1.2.2. Objective - 2
- 1.2.3. Objective - 3
- 1.3. Research Methodology
- 1.4. Information Procurement
- 1.4.1. Purchased Database
- 1.4.2. GVR’s Internal Database
- 1.4.3. Secondary Sources
- 1.4.4. Primary Research
- 1.5. Information or Data Analysis
- 1.5.1. Data Analysis Models
- 1.6. Market Formulation & Validation
- 1.7. Model Details
- 1.7.1. Commodity Flow Analysis
- 1.8. List of Secondary Sources
- 1.9. List of Abbreviations
- 1.10. List of Primary Sources
- Chapter 2. Executive Summary
- 2.1. Market Snapshot
- 2.2. Segment Snapshot
- 2.3. Competitive Landscape Snapshot
- Chapter 3. Market Variables, Trends, & Scope
- 3.1. Market Segmentation and Scope
- 3.2. Market Lineage Outlook
- 3.2.1. Parent Market Outlook
- 3.2.2. Related/Ancillary Market Outlook
- 3.3. Market Dynamics
- 3.4. Market Drivers
- 3.4.1. Rising Prevalence of Liver Diseases
- 3.4.2. Advancements in Diagnostic Technologies
- 3.4.3. Expansion of Preventive Healthcare & Screening Programs
- 3.5. Market Restraint Analysis
- 3.5.1. Limited Awareness in Low-Income Regions
- 3.5.2. Cost & Infrastructure Barriers
- 3.6. Business Environment Analysis
- 3.6.1. SWOT Analysis; By Factor (Political & Legal, Economic And Technological)
- 3.6.2. Porter’s Five Forces Analysis
- Chapter 4. Test Type Business Analysis
- 4.1. Transaminase Test Market: Test Type Movement Analysis
- 4.2. ALT Test
- 4.2.1. ALT Test Market, 2021 - 2033 (USD Million)
- 4.3. AST Test
- 4.3.1. AST Test Market, 2021 - 2033 (USD Million)
- 4.4. Combined Transaminase Panels
- 4.4.1. Combined Transaminase Panels Market, 2021 - 2033 (USD Million)
- 4.5. Others
- 4.5.1. Others Market, 2021 - 2033 (USD Million)
- Chapter 5. Technology Business Analysis
- 5.1. Transaminase Test Market: Technology Movement Analysis
- 5.2. Automated Analyzers
- 5.2.1. Automated Analyzers Market, 2021 - 2033 (USD Million)
- 5.3. Semi-Automated & Manual Systems
- 5.3.1. Semi-Automated & Manual Systems Market, 2021 - 2033 (USD Million)
- 5.4. Point-of-Care (POC) Devices
- 5.4.1. Point-of-Care (POC) Devices Market, 2021 - 2033 (USD Million)
- 5.5. Paper-Based / Lab-on-a-Chip Platforms
- 5.5.1. Paper-Based / Lab-on-a-Chip Platforms Market, 2021 - 2033 (USD Million)
- 5.6. Others
- 5.6.1. Others Market, 2021 - 2033 (USD Million)
- Chapter 6. Application Business Analysis
- 6.1. Transaminase Test Market: Application Movement Analysis
- 6.2. Liver Disease Diagnosis & Monitoring
- 6.2.1. Liver Disease Diagnosis & Monitoring Market, 2021 - 2033 (USD Million)
- 6.3. Hepatitis Screening
- 6.3.1. Hepatitis Screening Market, 2021 - 2033 (USD Million)
- 6.4. Drug-Induced Liver Injury (DILI) Monitoring
- 6.5. Others
- 6.5.1. Others Market, 2021 - 2033 (USD Million)
- Chapter 7. End Use Business Analysis
- 7.1. Transaminase Test Market: End Use Movement Analysis
- 7.2. Hospitals & Clinics
- 7.2.1. Hospitals & Clinics Market, 2021 - 2033 (USD Million)
- 7.3. Diagnostic Laboratories (centralized testing)
- 7.3.1. Diagnostic Laboratories (centralized testing) Market, 2021 - 2033 (USD Million)
- 7.4. Research Institutes
- 7.4.1. Research Institutes Market, 2021 - 2033 (USD Million)
- 7.5. Home Testing
- 7.5.1. Home Testing Market, 2021 - 2033 (USD Million)
- 7.6. Others
- 7.6.1. Others Market, 2021 - 2033 (USD Million)
- Chapter 8. Regional Business Analysis
- 8.1. Transaminase Test Market Share By Region, 2024 & 2033
- 8.2. North America
- 8.2.1. North America Transaminase Test market, 2021 - 2033 (USD Million)
- 8.2.2. U.S.
- 8.2.2.1. Key Country Dynamics
- 8.2.2.2. Target Disease Prevalence
- 8.2.2.3. Competitive Scenario
- 8.2.2.4. Regulatory Framework
- 8.2.2.5. Reimbursement Scenario
- 8.2.2.6. U.S. Transaminase Test market, 2021 - 2033 (USD MILLION)
- 8.2.3. Canada
- 8.2.3.1. Key Country Dynamics
- 8.2.3.2. Target Disease Prevalence
- 8.2.3.3. Competitive Scenario
- 8.2.3.4. Regulatory Framework
- 8.2.3.5. Reimbursement Scenario
- 8.2.3.6. Canada Transaminase Test market, 2021 - 2033 (USD Million)
- 8.2.4. Mexico
- 8.2.4.1. Key Country Dynamics
- 8.2.4.2. Target Disease Prevalence
- 8.2.4.3. Competitive Scenario
- 8.2.4.4. Regulatory Framework
- 8.2.4.5. Reimbursement Scenario
- 8.2.4.6. Mexico Transaminase Test market, 2021 - 2033 (USD Million)
- 8.3. Europe
- 8.3.1. Europe Transaminase Test market, 2021 - 2033 (USD Million)
- 8.3.2. Germany
- 8.3.2.1. Key Country Dynamics
- 8.3.2.2. Target Disease Prevalence
- 8.3.2.3. Competitive Scenario
- 8.3.2.4. Regulatory Framework
- 8.3.2.5. Reimbursement Scenario
- 8.3.2.6. Germany Transaminase Test market, 2021 - 2033 (USD Million)
- 8.3.3. UK
- 8.3.3.1. Key Country Dynamics
- 8.3.3.2. Target Disease Prevalence
- 8.3.3.3. Competitive Scenario
- 8.3.3.4. Regulatory Framework
- 8.3.3.5. Reimbursement Scenario
- 8.3.3.6. UK Transaminase Test market, 2021 - 2033 (USD Million)
- 8.3.4. France
- 8.3.4.1. Key Country Dynamics
- 8.3.4.2. Target Disease Prevalence
- 8.3.4.3. Competitive Scenario
- 8.3.4.4. Regulatory Framework
- 8.3.4.5. Reimbursement Scenario
- 8.3.4.6. France Transaminase Test market, 2021 - 2033 (USD Million)
- 8.3.5. Italy
- 8.3.5.1. Key Country Dynamics
- 8.3.5.2. Target Disease Prevalence
- 8.3.5.3. Competitive Scenario
- 8.3.5.4. Regulatory Framework
- 8.3.5.5. Reimbursement Scenario
- 8.3.5.6. Italy Transaminase Test market, 2021 - 2033 (USD Million)
- 8.3.6. Spain
- 8.3.6.1. Key Country Dynamics
- 8.3.6.2. Target Disease Prevalence
- 8.3.6.3. Competitive Scenario
- 8.3.6.4. Regulatory Framework
- 8.3.6.5. Reimbursement Scenario
- 8.3.6.6. Spain Transaminase Test market, 2021 - 2033 (USD Million)
- 8.3.7. Denmark
- 8.3.7.1. Key Country Dynamics
- 8.3.7.2. Target Disease Prevalence
- 8.3.7.3. Competitive Scenario
- 8.3.7.4. Regulatory Framework
- 8.3.7.5. Reimbursement Scenario
- 8.3.7.6. Denmark Transaminase Test market, 2021 - 2033 (USD Million)
- 8.3.8. Sweden
- 8.3.8.1. Key Country Dynamics
- 8.3.8.2. Target Disease Prevalence
- 8.3.8.3. Competitive Scenario
- 8.3.8.4. Regulatory Framework
- 8.3.8.5. Reimbursement Scenario
- 8.3.8.6. Sweden Transaminase Test market, 2021 - 2033 (USD Million)
- 8.3.9. Norway
- 8.3.9.1. Key Country Dynamics
- 8.3.9.2. Target Disease Prevalence
- 8.3.9.3. Competitive Scenario
- 8.3.9.4. Regulatory Framework
- 8.3.9.5. Reimbursement Scenario
- 8.3.9.6. Norway Transaminase Test market, 2021 - 2033 (USD Million)
- 8.4. Asia Pacific
- 8.4.1. Asia Pacific Transaminase Test market, 2021 - 2033 (USD Million)
- 8.4.2. Japan
- 8.4.2.1. Key Country Dynamics
- 8.4.2.2. Target Disease Prevalence
- 8.4.2.3. Competitive Scenario
- 8.4.2.4. Regulatory Framework
- 8.4.2.5. Reimbursement Scenario
- 8.4.2.6. Japan Transaminase Test market, 2021 - 2033 (USD Million)
- 8.4.3. China
- 8.4.3.1. Key Country Dynamics
- 8.4.3.2. Target Disease Prevalence
- 8.4.3.3. Competitive Scenario
- 8.4.3.4. Regulatory Framework
- 8.4.3.5. Reimbursement Scenario
- 8.4.3.6. China Transaminase Test market, 2021 - 2033 (USD Million)
- 8.4.4. India
- 8.4.4.1. Key Country Dynamics
- 8.4.4.2. Target Disease Prevalence
- 8.4.4.3. Competitive Scenario
- 8.4.4.4. Regulatory Framework
- 8.4.4.5. Reimbursement Scenario
- 8.4.4.6. India Transaminase Test market, 2021 - 2033 (USD Million)
- 8.4.5. South Korea
- 8.4.5.1. Key Country Dynamics
- 8.4.5.2. Target Disease Prevalence
- 8.4.5.3. Competitive Scenario
- 8.4.5.4. Regulatory Framework
- 8.4.5.5. Reimbursement Scenario
- 8.4.5.6. South Korea Transaminase Test market, 2021 - 2033 (USD Million)
- 8.4.6. Australia
- 8.4.6.1. Key Country Dynamics
- 8.4.6.2. Target Disease Prevalence
- 8.4.6.3. Competitive Scenario
- 8.4.6.4. Regulatory Framework
- 8.4.6.5. Reimbursement Scenario
- 8.4.6.6. Australia Transaminase Test market, 2021 - 2033 (USD Million)
- 8.4.7. Thailand
- 8.4.7.1. Key Country Dynamics
- 8.4.7.2. Target Disease Prevalence
- 8.4.7.3. Competitive Scenario
- 8.4.7.4. Regulatory Framework
- 8.4.7.5. Reimbursement Scenario
- 8.4.7.6. Thailand Transaminase Test market, 2021 - 2033 (USD Million)
- 8.5. Latin America
- 8.5.1. Latin America Transaminase Test market, 2021 - 2033 (USD Million)
- 8.5.2. Brazil
- 8.5.2.1. Key Country Dynamics
- 8.5.2.2. Target Disease Prevalence
- 8.5.2.3. Competitive Scenario
- 8.5.2.4. Regulatory Framework
- 8.5.2.5. Reimbursement Scenario
- 8.5.2.6. Brazil Transaminase Test market, 2021 - 2033 (USD Million)
- 8.5.3. Argentina
- 8.5.3.1. Key Country Dynamics
- 8.5.3.2. Target Disease Prevalence
- 8.5.3.3. Competitive Scenario
- 8.5.3.4. Regulatory Framework
- 8.5.3.5. Reimbursement Scenario
- 8.5.3.6. Argentina Transaminase Test market, 2021 - 2033 (USD Million)
- 8.6. MEA
- 8.6.1. MEA Transaminase Test market, 2021 - 2033 (USD Million)
- 8.6.2. South Africa
- 8.6.2.1. Key Country Dynamics
- 8.6.2.2. Target Disease Prevalence
- 8.6.2.3. Competitive Scenario
- 8.6.2.4. Regulatory Framework
- 8.6.2.5. Reimbursement Scenario
- 8.6.2.6. South Africa Transaminase Test market, 2021 - 2033 (USD Million)
- 8.6.3. Saudi Arabia
- 8.6.3.1. Key Country Dynamics
- 8.6.3.2. Target Disease Prevalence
- 8.6.3.3. Competitive Scenario
- 8.6.3.4. Regulatory Framework
- 8.6.3.5. Reimbursement Scenario
- 8.6.3.6. Saudi Arabia Transaminase Test market, 2021 - 2033 (USD Million)
- 8.6.4. UAE
- 8.6.4.1. Key Country Dynamics
- 8.6.4.2. Target Disease Prevalence
- 8.6.4.3. Competitive Scenario
- 8.6.4.4. Regulatory Framework
- 8.6.4.5. Reimbursement Scenario
- 8.6.4.6. UAE Transaminase Test market, 2021 - 2033 (USD Million)
- 8.6.5. Kuwait
- 8.6.5.1. Key Country Dynamics
- 8.6.5.2. Target Disease Prevalence
- 8.6.5.3. Competitive Scenario
- 8.6.5.4. Regulatory Framework
- 8.6.5.5. Reimbursement Scenario
- 8.6.5.6. Kuwait Transaminase Test market, 2021 - 2033 (USD Million)
- Chapter 9. Competitive Landscape
- 9.1. Participant’s overview
- 9.2. Financial performance
- 9.3. Participant categorization
- 9.3.1. Market Leaders
- 9.3.2. Transaminase Test Market Share Analysis, 2024
- 9.3.3. Company Profiles
- 9.3.3.1. F. Hoffmann-La Roche AG
- 9.3.3.1.1. Company Overview
- 9.3.3.1.2. Financial Performance
- 9.3.3.1.3. Product Benchmarking
- 9.3.3.1.4. Strategic Initiatives
- 9.3.3.2. Abbott
- 9.3.3.2.1. Company Overview
- 9.3.3.2.2. Financial Performance
- 9.3.3.2.3. Product Benchmarking
- 9.3.3.2.4. Strategic Initiatives
- 9.3.3.3. Thermo Fisher Scientific
- 9.3.3.3.1. Company Overview
- 9.3.3.3.2. Financial Performance
- 9.3.3.3.3. Product Benchmarking
- 9.3.3.3.4. Strategic Initiatives
- 9.3.3.4. Siemens Healthineers
- 9.3.3.4.1. Company Overview
- 9.3.3.4.2. Financial Performance
- 9.3.3.4.3. Product Benchmarking
- 9.3.3.4.4. Strategic Initiatives
- 9.3.3.5. Danaher
- 9.3.3.5.1. Company Overview
- 9.3.3.5.2. Financial Performance
- 9.3.3.5.3. Product Benchmarking
- 9.3.3.5.4. Strategic Initiatives
- 9.3.3.6. Randox Laboratories Ltd
- 9.3.3.6.1. Company Overview
- 9.3.3.6.2. Financial Performance
- 9.3.3.6.3. Product Benchmarking
- 9.3.3.6.4. Strategic Initiatives
- 9.3.3.7. ELITechGroup
- 9.3.3.7.1. Company Overview
- 9.3.3.7.2. Financial Performance
- 9.3.3.7.3. Product Benchmarking
- 9.3.3.7.4. Strategic Initiatives
- 9.3.3.8. Horiba Medical
- 9.3.3.8.1. Company Overview
- 9.3.3.8.2. Financial Performance
- 9.3.3.8.3. Product Benchmarking
- 9.3.3.8.4. Strategic Initiatives
- 9.3.3.9. Alpha Laboratories
- 9.3.3.9.1. Company Overview
- 9.3.3.9.2. Financial Performance
- 9.3.3.9.3. Product Benchmarking
- 9.3.3.9.4. Strategic Initiatives
- 9.3.3.10. Laboratory Corporation of America Holdings (LabCorp)
- 9.3.3.10.1. Company Overview
- 9.3.3.10.2. Financial Performance
- 9.3.3.10.3. Product Benchmarking
- 9.3.3.10.4. Strategic Initiatives
- 9.3.3.11. Bio-Rad Laboratories, Inc.
- 9.3.3.11.1. Company Overview
- 9.3.3.11.2. Financial Performance
- 9.3.3.11.3. Product Benchmarking
- 9.3.3.11.4. Strategic Initiatives
- 9.3.3.12. bioMérieux
- 9.3.3.12.1. Company Overview
- 9.3.3.12.2. Financial Performance
- 9.3.3.12.3. Product Benchmarking
- 9.3.3.12.4. Strategic Initiatives
- 9.3.4. Strategy Mapping
- 9.3.4.1. Expansion
- 9.3.4.2. Acquisition
- 9.3.4.3. Collaborations
- 9.3.4.4. Disease Type/Drug Class Launch
- 9.3.4.5. Partnerships
- 9.3.4.6. Others
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
